Abstract Preview Page

This is an automatically generated preview of the abstract you selected.

Luciferase imaging accelerates analyses of antineoplastic therapy in animal models Robert, S. Negrin* Bone Marrow Transplant, Dept. of Medicine, Stanford, CA 94305, USA      *(negrs@leland.Stanford.EDU) Development of novel therapies for cancer can be greatly enhanced with animal models that are more rapid and predictive of the human response. We have developed a whole body bioluminescent imaging method that allows quantitative assessment of tumor cell growth and the response to therapy in living animal models of human disease. With this method we have investigated the in vivo tumorcidal capability of activated T cell that have natural killer (NK) activity, and the ability to redirect this activity with bispecific (Bs) antibodies. In vitro, the Bs antibody HER-2/neuxCD3 substantially increased the cytotoxicity of NK T cells to otherwise poor tumor targets. Utilizing whole body imaging we have demonstrated that the kinetics of tumor cell growth could be assessed. More rapid and sustained therapeutic responses were apparent in animals treated with NK T cells and the HER-2/neu x CD3 Bs antibody than in animals treated with the antibody, Herceptin, alone. In mice, long-term survival directly correlated to the light intensity from luciferase labeled tumor cells. We have demonstrated that rapid, quantitative whole body analyses of tumor burden and response to therapies, which can dramatically accelerate the discovery process. [Talk: negrin.robert.81431]

Return to the list of abstracts

E-mail   |  Conference Info  |   Index of Abstracts